放射学阳性中轴型脊柱关节炎患者抗英夫利西单抗抗体的长期随访:药物生存与减量的标志物
研究对60例接受英夫利西单抗(IFX)治疗的放射学阳性中轴型脊柱关节炎患者进行前瞻性队列的回顾性分析,检测基线和多个时间点的抗IFX抗体。27例(45%)检出抗IFX抗体,其减量生存期更短(9.9个月 vs 63.4个月,P=0.004),IFX总体生存更差(P<0.001),但换用第二种TNFi后3个月和6个月临床应答更好。
要点
- 45%患者检出抗IFX抗体,其中85.1%在治疗第一年内出现。
- 抗IFX抗体阳性者减量生存期更短(9.9个月 vs 63.4个月,P=0.004)。
- 抗IFX抗体阳性者换用第二种TNFi后3个月和6个月应答率更高。
核心结论
- 抗IFX抗体是减量生存期缩短的参数,支持检测抗体以指导临床决策。
- 长期队列证实抗IFX抗体与更差的IFX表现相关,并可预测第二种TNFi的良好临床应答。
研究设计与样本
- 前瞻性队列的回顾性分析,纳入60例接受IFX治疗的放射学阳性中轴型脊柱关节炎患者。
- 在基线、第6周、第12至14周、第22至24周、第48至54周、第96至102周以及减量或换药前评估临床/实验室数据、IFX水平和抗IFX抗体。
主要发现
- 27例(45%)检出抗IFX抗体,其中23例(85.1%)在IFX治疗第一年内转为阳性。
- 抗IFX抗体阳性组与阴性组相比,甲氨蝶呤联用更少(5例[18.5%] vs 14例[42.4%],P=0.048)。
- 抗IFX抗体阳性组在第22至24周(P=0.020)和第48至54周(P=0.034)输注反应更多,第48至54周治疗失败更多(P=0.028)。
- 抗IFX抗体阳性组IFX总体生存期缩短(P<0.001),持续应答率更低(P=0.044)。
- 抗IFX抗体阳性组减量生存期更短(9.9个月[95%CI 4.0-15.8] vs 63.4个月[95%CI 27.9-98.8],P=0.004)。
关键数值与推荐
- IFX治疗失败后换用第二种TNFi,抗IFX抗体阳性组3个月临床应答率高于阴性组(15例[83.3%] vs 3例[27.3%],P=0.005)。
- 换用第二种TNFi后6个月,抗IFX抗体阳性组临床应答率仍高于阴性组(15例[83.3%] vs 4例[36.4%],P=0.017)。
临床怎么用
- 原文结论认为抗IFX抗体检测可指导临床决策,未给出具体推荐方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The aim of this study was to evaluate the influence of anti-infliximab (IFX) antibodies on three different points of care: response/tolerance to IFX, tapering strategy, and in a subsequent treatment with a second tumor necrosis factor inhibitor (TNFi). METHODS: A prospective cohort of 60 patients with radiographic axial spondyloarthritis who received IFX were evaluated retrospectively regarding clinical/laboratorial data, IFX levels, and anti-IFX antibodies at baseline, after 6, 12 to 14, 22 to 24, 48 to 54, 96 to 102 weeks, and before tapering or switching. RESULTS: Anti-IFX antibodies were detected in 27 patients (45%), of whom 23 (85.1%) became positive in the first year of IFX treatment. In comparison to the group that was negative for anti-IFX antibodies, patients who were positive for anti-IFX antibodies demonstrated the following: less use of methotrexate as a concomitant treatment to IFX (5 [18.5%] vs 14 [42.4%]; P = 0.048), more infusion reactions at 22 to 24 weeks (P = 0.020) and 48 to 54 weeks (P = 0.034), more treatment failures (P = 0.028) at 48 to 54 weeks, reduced overall IFX survival (P < 0.001), and lower sustained responses (P = 0.044). Of note, patients who were positive for anti-IFX antibodies exhibited a shorter tapering survival (9.9 months [95% confidence interval (CI) 4.0-15.8] vs 63.4 months [95% CI 27.9-98.8]; P = 0.004) in comparison with patients who were negative for anti-IFX antibodies. Conversely, for patients who failed IFX, patients who were positive for anti-IFX antibodies had better clinical response to the second TNFi at three months (15 [83.3%] vs 3 [27.3%]; P = 0.005) and six months (15 [83.3%] vs 4 [36.4%]; P = 0.017) than the patients who were negative for anti-IFX antibodies after switching. CONCLUSION: This study provided novel data that anti-IFX antibodies is a parameter for reduced tapering survival, reinforcing its detection to guide clinical decision. Additionally, we confirmed in a long-term cohort the anti-IFX antibody association with worse IFX performance and as predictor of the second TNFi good clinical response.
引用
- Pimentel CQ, Medeiros-Ribeiro AC, Shimabuco AY, et al. Long-Term Follow-Up of Anti-Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering. Arthritis Rheumatol. 2024. PMID: 38801195. doi:10.1002/art.42923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。